{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:13:49Z","timestamp":1790936029227,"version":"4.1.0"},"reference-count":116,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2005,6]]},"DOI":"10.1016\/j.semarthrit.2004.11.006","type":"journal-article","created":{"date-parts":[[2005,5,27]],"date-time":"2005-05-27T15:02:16Z","timestamp":1117206136000},"page":"819-836","source":"Crossref","is-referenced-by-count":158,"title":["The Benefit\/Risk Profile of TNF-Blocking Agents: Findings of a Consensus Panel"],"prefix":"10.1016","volume":"34","author":[{"given":"Marc C.","family":"Hochberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark G.","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott E.","family":"Plevy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn F.","family":"Hobbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Yocum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2004.11.006_bib1","unstructured":"Immunex Corp. Enbrel [package insert]. Seattle, WA, 2002."},{"key":"10.1016\/j.semarthrit.2004.11.006_bib2","unstructured":"Centocor Inc. Remicade [package insert]. Malvern, PA, 2003."},{"key":"10.1016\/j.semarthrit.2004.11.006_bib3","unstructured":"Abbott Laboratories. Humira [package insert]. North Chicago, IL, 2003."},{"key":"10.1016\/j.semarthrit.2004.11.006_bib4","first-page":"841","article-title":"Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy","volume":"27","author":"Kavanaugh","year":"2000","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib5","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/0092-8674(94)90372-7","article-title":"The TNF receptor superfamily of cellular and viral proteins","volume":"76","author":"Smith","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib6","doi-asserted-by":"crossref","first-page":"478","DOI":"10.7326\/0003-4819-130-6-199903160-00004","article-title":"Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial","volume":"130","author":"Moreland","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib7","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","article-title":"Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis","volume":"41","author":"Maini","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib8","first-page":"168","article-title":"Efficacy and safety of adalimumab (D2E7), the first fully human anti-TNF monoclonal antibody in patients with rheumatoid arthritis who failed previous DMARD therapy","volume":"61","author":"Van de Putte","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib9","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/art.10148","article-title":"Guidelines for the management of rheumatoid arthritis","volume":"46","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib10","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/art.20019","article-title":"Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis","volume":"50","author":"Keystone","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib11","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1056\/NEJM199901283400401","article-title":"A trial of etanercept, a recombinant tumor necrosis factor receptor","volume":"340","author":"Weinblatt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib12","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib13","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","article-title":"Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate","volume":"48","author":"Weinblatt","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"Suppl. 2","key":"10.1016\/j.semarthrit.2004.11.006_bib14","first-page":"ii13","article-title":"Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis","volume":"62","author":"Hochberg","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib15","article-title":"Adalimumab (D2E7), a fully human anti-TNF\u2014a monoclonal antibody, inhibits the progression of structural joint damage in patients with active RA despite concomitant methotrexate therapy","volume":"46","author":"Keystone","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib16","first-page":"2563","article-title":"Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis","volume":"30","author":"Furst","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib17","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis","volume":"343","author":"Lipsky","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib18","series-title":"Treatment of early rheumatoid arthritis with infliximab plus methotrexate or methotrexate alone preliminary results of the ASPIRE trial","author":"Smolen","year":"2003"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib19","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(04)15640-7","article-title":"Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis","volume":"363","author":"Klareskog","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib20","first-page":"789","article-title":"The dimensions of health outcomes","volume":"9","author":"Fries","year":"1982","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib21","article-title":"102-week clinical and radiologic results from the ATTRACT trial","volume":"60","author":"Maini","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib22","article-title":"The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis","volume":"46","author":"Hansen","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib23","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1136\/ard.2003.009589","article-title":"Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa","volume":"62","author":"van Vollenhoven","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib24","first-page":"2315","article-title":"Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis?","volume":"30","author":"Ang","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib25","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis","volume":"356","author":"Mease","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib26","article-title":"The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT)","volume":"46","author":"Antoni","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib27","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/ard.62.9.817","article-title":"International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis","volume":"62","author":"Braun","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib28","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJMoa012664","article-title":"Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha","volume":"346","author":"Gorman","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib29","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","article-title":"Treatment of active ankylosing spondylitis with infliximab","volume":"359","author":"Braun","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib30","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn\u2019s disease","volume":"337","author":"Targan","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib31","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0016-5085(76)80163-1","article-title":"Development of a Crohn\u2019s disease activity index. National Cooperative Crohn\u2019s Disease Study","volume":"70","author":"Best","year":"1976","journal-title":"Gastroenterology"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib32","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn\u2019s disease","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib33","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1111\/j.1572-0241.2003.07674.x","article-title":"The effects of infliximab maintenance therapy on health-related quality of life","volume":"98","author":"Feagan","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib34","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1136\/gut.30.7.983","article-title":"Development and validation of an endoscopic index of the severity for Crohn\u2019s disease","volume":"30","author":"Mary","year":"1989","journal-title":"Gut"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib35","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S0016-5085(99)70005-3","article-title":"Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn\u2019s disease","volume":"116","author":"D\u2019Haens","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib36","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","article-title":"Etanercept for active Crohn\u2019s disease","volume":"121","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib37","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1046\/j.1365-2036.2003.01414.x","article-title":"Treatment of active Crohn\u2019s disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor)","volume":"17","author":"Rutgeerts","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib38","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohn\u2019s disease","volume":"340","author":"Present","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib39","first-page":"81","article-title":"Long-term treatment of fistulizing Crohn\u2019s disease","volume":"122","author":"Sands","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib40","series-title":"Response to infliximab in fistulizing Crohn\u2019s disease is independent of baseline number of draining fistulas","author":"Sands","year":"2003"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib41","series-title":"Infliximab is not a bridge to immunomodulators in Crohns disease","author":"Tuvlin","year":"2003"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib42","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/00054725-200105000-00001","article-title":"Infliximab in the treatment of severe, steroid-refractory ulcerative colitis","volume":"7","author":"Sands","year":"2001","journal-title":"Inflamm Bowel Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.semarthrit.2004.11.006_bib43","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1002\/ibd.3780070507","article-title":"Infliximab for patients with refractory ulcerative colitis","volume":"7","author":"Chey","year":"2001","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib44","doi-asserted-by":"crossref","first-page":"S310","DOI":"10.1016\/S0002-9270(01)03761-3","article-title":"Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis","volume":"96","author":"Su","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib45","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/00005176-200203000-00017","article-title":"Infliximab as a novel therapy for pediatric ulcerative colitis","volume":"34","author":"Mamula","year":"2002","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib46","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1136\/gut.52.7.998","article-title":"Infliximab in moderately severe glucocorticoid resistant ulcerative colitis","volume":"52","author":"Probert","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib47","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1046\/j.1365-2036.2003.01535.x","article-title":"Infliximab in refractory pouchitis complicated by fistulae following ileo-anal pouch for ulcerative colitis","volume":"17","author":"Viscido","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib48","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1111\/j.1572-0241.2003.07581.x","article-title":"Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease","volume":"98","author":"Regueiro","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib49","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/S0140-6736(03)12954-6","article-title":"Psoriasis","volume":"361","author":"Lebwohl","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib50","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/S0140-6736(00)04954-0","article-title":"Efficacy and safety of infliximab monotherapy for plaque-type psoriasis","volume":"357","author":"Chaudhari","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib51","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1067\/mjd.2002.120472","article-title":"Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab","volume":"46","author":"Schopf","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib52","series-title":"Infliximab in the treatment of psoriasis","author":"Gottlieb","year":"2003"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib53","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa030409","article-title":"Etanercept as monotherapy in patients with psoriasis","volume":"349","author":"Leonardi","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib54","first-page":"1571","article-title":"Infliximab (anti-tumor necrosis factor alpha antibody)","volume":"137","author":"Voigtlander","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib55","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/00054725-200111000-00008","article-title":"Hidradenitis suppurativa and Crohn\u2019s disease","volume":"7","author":"Martinez","year":"2001","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib56","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1067\/mjd.2001.119100","article-title":"Treatment of recalcitrant cicatricial pemphigoid with the tumor necrosis factor alpha antagonist etanercept","volume":"46","author":"Sacher","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib57","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJM200111223452118","article-title":"Successful treatment of Langerhans\u2019-cell histiocytosis with etanercept","volume":"345","author":"Henter","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib58","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/1529-0131(200105)44:5<1149::AID-ANR197>3.0.CO;2-F","article-title":"Etanercept combined with conventional treatment in Wegener\u2019s granulomatosis","volume":"44","author":"Stone","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib59","first-page":"1864","article-title":"Etanercept ameliorates sarcoidosis arthritis and skin disease","volume":"30","author":"Khanna","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib60","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1067\/mjd.2003.228","article-title":"Progressive cutaneous sarcoidosis responding to anti-tumor necrosis factor-alpha therapy","volume":"48","author":"Mallbris","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib61","first-page":"413","article-title":"The use of infliximab in cutaneous sarcoidosis","volume":"2","author":"Meyerle","year":"2003","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib62","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1365-2133.2004.05769.x","article-title":"Infliximab therapy for sarcoidosis (lupus pernio)","volume":"150","author":"Haley","year":"2004","journal-title":"Br J Dermatol"},{"issue":"Suppl. 2","key":"10.1016\/j.semarthrit.2004.11.006_bib63","doi-asserted-by":"crossref","first-page":"ii51","DOI":"10.1136\/ard.61.suppl_2.ii51","article-title":"Behcet\u2019s disease","volume":"61","author":"Sfikakis","year":"2002","journal-title":"Ann Rheum Dis"},{"issue":"Suppl. 2","key":"10.1016\/j.semarthrit.2004.11.006_bib64","doi-asserted-by":"crossref","first-page":"ii88","DOI":"10.1136\/ard.61.suppl_2.ii88","article-title":"Pharmacovigilance","volume":"61","author":"Simon","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib65","series-title":"Safety and efficacy update on approved TNF-blocking agents","year":"2003"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib66","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S1521-6942(03)00041-X","article-title":"Co-morbidity in rheumatoid arthritis","volume":"17","author":"Mikuls","year":"2003","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib67","article-title":"Response to pneumococcal vaccination in psoriatic arthritis patients treated with etanercept (Enbrel\u00ae)","volume":"61","author":"Mease","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib68","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib69","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S1473-3099(03)00545-0","article-title":"Anti-tumour necrosis factor agents and tuberculosis risk","volume":"3","author":"Gardam","year":"2003","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib70","series-title":"FDA Meeting March 2003: update on the safety of new drugs for rheumatoid arthritis. Part II: CHF, infection and other safety issues","year":"2003"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib71","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/art.11137","article-title":"Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk","volume":"48","author":"Gomez-Reino","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib72","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1002\/art.11134","article-title":"Tuberculosis in the cytokine era","volume":"48","author":"Hamilton","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib73","first-page":"1436","article-title":"Increased risk of tuberculosis in patients with rheumatoid arthritis","volume":"30","author":"Carmona","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib74","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1164\/rccm.167.4.603","article-title":"Treatment of tuberculosis","volume":"167","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib75","unstructured":"Centers for Disease Control and Prevention. Dear Colleague Letter. Available at: http:\/\/www.cdc.gov\/nchstp\/tb\/dearcolleague_8_9_03.htm. Accessed 28 October 2003, 2003."},{"key":"10.1016\/j.semarthrit.2004.11.006_bib76","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1002\/art.10583","article-title":"Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept","volume":"46","author":"Lee","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib77","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/00002281-200305000-00002","article-title":"Infectious complications of biologic treatments of rheumatoid arthritis","volume":"15","author":"Mohan","year":"2003","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib78","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/01.CIR.0000124490.27666.B2","article-title":"Targeted anticytokine therapy in patients with chronic heart failure","volume":"109","author":"Mann","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib79","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","article-title":"Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure","volume":"107","author":"Chung","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib80","doi-asserted-by":"crossref","first-page":"807","DOI":"10.7326\/0003-4819-138-10-200305200-00008","article-title":"Case reports of heart failure after therapy with a tumor necrosis factor antagonist","volume":"138","author":"Kwon","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib81","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.amjmed.2003.09.039","article-title":"Heart failure in rheumatoid arthritis","volume":"116","author":"Wolfe","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib82","unstructured":"American College of Rheumatology Hotline. FDA Meeting March 2003: update on the safety of new drugs for rheumatoid arthritis. Part I: The risk of lymphoma with rheumatoid arthritis (RA) and TNF inhibitors. Available at: http:\/\/www.rheumatology.org\/publications\/hotline\/0303tnfl.asp. Accessed 28th October, 2003."},{"key":"10.1016\/j.semarthrit.2004.11.006_bib83","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/jnci\/85.4.307","article-title":"Incidence of cancer among patients with rheumatoid arthritis","volume":"85","author":"Gridley","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib84","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/0959-8049(96)00210-9","article-title":"Rheumatoid arthritis and cancer risk","volume":"32A","author":"Mellemkjaer","year":"1996","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib85","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/art.10939","article-title":"Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives","volume":"48","author":"Ekstrom","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib86","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/00054725-200105000-00005","article-title":"The incidence of lymphoid and myeloid malignancies among hospitalized Crohn\u2019s disease patients","volume":"7","author":"Arseneau","year":"2001","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib87","first-page":"778","article-title":"The risk of malignancy associated with psoriasis","volume":"137","author":"Margolis","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib88","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/bmj.317.7152.180","article-title":"Disease activity and risk of lymphoma in patients with rheumatoid arthritis","volume":"317","author":"Baecklund","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib89","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1053\/gast.2001.29271","article-title":"Lymphoma risk in inflammatory bowel disease","volume":"121","author":"Loftus","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib90","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1053\/gast.2002.30328","article-title":"Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine","volume":"122","author":"Dayharsh","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib91","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/00002281-200403000-00006","article-title":"Comorbid conditions in patients with rheumatic diseases","volume":"16","author":"Wasko","year":"2004","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib92","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/art.20311","article-title":"Lymphoma in rheumatoid arthritis","volume":"50","author":"Wolfe","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib93","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W","article-title":"Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides","volume":"44","author":"Mohan","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib94","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1212\/WNL.53.3.457","article-title":"TNF neutralization in MS","volume":"53","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib95","article-title":"The effects of antibodies to infliximab on ACR response in patients with rheumatoid arthritis in the ATTRACT study","volume":"46","author":"Wagner","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib96","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn\u2019s disease","volume":"348","author":"Baert","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib97","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1053\/gast.2003.50145","article-title":"Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn\u2019s disease","volume":"124","author":"Farrell","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib98","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00002281-200001000-00008","article-title":"Musculoskeletal and systemic reactions to biological therapeutic agents","volume":"12","author":"Watts","year":"2000","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib99","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1002\/1529-0131(200011)43:11<2383::AID-ANR2>3.0.CO;2-D","article-title":"Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha","volume":"43","author":"Charles","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib100","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s10067-002-0654-5","article-title":"Anti-TNF-alpha-induced systemic lupus syndrome","volume":"22","author":"Debandt","year":"2003","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib101","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1191\/0961203302lu236cr","article-title":"Drug-induced lupus following treatment with infliximab in rheumatoid arthritis","volume":"11","author":"Favalli","year":"2002","journal-title":"Lupus"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib102","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/S1590-8658(03)00448-1","article-title":"Infliximab-induced lupus in Crohn\u2019s disease","volume":"35","author":"Sarzi-Puttini","year":"2003","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib103","first-page":"276","article-title":"Drug-induced systemic lupus erythematosus associated with etanercept therapy in a child with juvenile idiopathic arthritis","volume":"21","author":"Lepore","year":"2003","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib104","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0140-6736(02)07714-0","article-title":"Drug-induced systemic lupus erythematosus associated with etanercept therapy","volume":"359","author":"Shakoor","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib105","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1046\/j.1365-2230.2003.01411.x","article-title":"Etanercept-induced systemic lupus erythematosus","volume":"28","author":"Swale","year":"2003","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib106","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1136\/ard.61.11.1031","article-title":"New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis","volume":"61","author":"Cairns","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib107","doi-asserted-by":"crossref","first-page":"625","DOI":"10.7326\/0003-4819-137-7-200210010-00030","article-title":"Infliximab-induced systemic lupus erythematosus","volume":"137","author":"Ali","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib108","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/j.1572-0241.2003.07457.x","article-title":"The incidence and management of infusion reactions to infliximab","volume":"98","author":"Cheifetz","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib109","unstructured":"Amgen. Kineret [package insert]. Thousand Oaks, CA, 2003."},{"key":"10.1016\/j.semarthrit.2004.11.006_bib110","first-page":"66","article-title":"A randomized double-blind controlled study evaluating the safety and efficacy of etanercept vs etanercept plus anakinra in patients with rheumatoid arthritis","volume":"62","author":"Genovese","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib111","first-page":"79","article-title":"Safety of combination therapy with anakinra and etanercept in patients with rheumatoid arthritis","volume":"44","author":"Schiff","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib112","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0190-9622(98)70508-0","article-title":"Methotrexate in psoriasis","volume":"38","author":"Roenigk","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib113","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S0190-9622(98)70325-1","article-title":"Cyclosporine consensus conference","volume":"39","author":"Lebwohl","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib114","first-page":"S152","article-title":"Outcome of pregnancy in women receiving Remicade (infliximab) for the treatment of Crohn\u2019s disease or rheumatoid arthritis","volume":"44","author":"Antoni","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib115","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2165\/00002018-200225030-00004","article-title":"Safety and efficacy of disease-modifying anti-rheumatic agents","volume":"25","author":"Fleischmann","year":"2002","journal-title":"Drug Saf"},{"key":"10.1016\/j.semarthrit.2004.11.006_bib116","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/00054725-200105000-00011","article-title":"Inflammatory bowel disease and pregnancy","volume":"7","author":"Katz","year":"2001","journal-title":"Inflamm Bowel Dis"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017204002410?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017204002410?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T12:32:02Z","timestamp":1586262722000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017204002410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":116,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["S0049017204002410"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2004.11.006","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2005,6]]}}}